Time filter

Source Type

Kimman M.,University of Sydney | Jan S.,University of Sydney | Kingston D.,University of New South Wales | Monaghan H.,University of Sydney | And 8 more authors.
Asian Pacific Journal of Cancer Prevention | Year: 2012

Cancer can be a major cause of poverty. This may be due either to the costs of treating and managing the illness as well as its impact upon people's ability to work. This is a concern that particularly affects countries that lack comprehensive social health insurance systems and other types of social safety nets. The ACTION study is a longitudinal cohort study of 10,000 hospital patients with a first time diagnosis of cancer. It aims to assess the impact of cancer on theeconomic circumstances of patients and their households, patients' quality of life, costs of treatment and survival. Patients will be followed throughout the first year after their cancer diagnosis, with interviews conducted at baseline (after diagnosis), three and 12 months. A cross-section of public and private hospitals as well as cancer centers across eight member countries of the Association of Southeast Asian Nations (ASEAN) will invite patients to participate. The primary outcome is incidence of financial catastrophe following treatment for cancer, defined as out-of-pocket health care expenditure at 12 months exceeding 30% of household income. Secondary outcomes include illness induced poverty, quality of life, psychological distress, economic hardship, survival and disease status. The findings can raise awareness of theextent of the cancer problem in South East Asia and its breadth in terms of its implications for households and the communities in which cancer patients live, identify priorities for further research and catalyze political action to put inplace effective cancer control policies.

Taokaew S.,Chulalongkorn University | Seetabhawang S.,Chulalongkorn University | Siripong P.,National Cancer Institute of Thailand | Phisalaphong M.,Chulalongkorn University
Materials | Year: 2013

A nanocellulose-gelatin (bacterial cellulose gelatin (BCG)) film was developed by a supplement of gelatin, at a concentration of 1%-10% w/v, in a coconut-water medium under the static cultivation of Acetobacter xylinum. The two polymers exhibited a certain degree of miscibility. The BCG film displayed dense and uniform homogeneous structures. The Fourier transform infrared spectroscopy (FTIR) results demonstrated interactions between the cellulose and gelatin. Incorporation of gelatin into a cellulose nanofiber network resulted in significantly improved optical transparency and water absorption capacity of the films. A significant drop in the mechanical strengths and a decrease in the porosity of the film were observed when the supplement of gelatin was more than 3% (w/v). The BCG films showed no cytotoxicity against Vero cells. © 2013 by the authors; licensee MDPI, Basel, Switzerland.

Matsuda A.,Japan National Institute of Advanced Industrial Science and Technology | Kuno A.,Japan National Institute of Advanced Industrial Science and Technology | Nakagawa T.,Japan National Institute of Advanced Industrial Science and Technology | Ikehara Y.,Japan National Institute of Advanced Industrial Science and Technology | And 10 more authors.
Analytical Chemistry | Year: 2015

Glycoform of mucin 1 (MUC1) in cancerous cells changes markedly with cell differentiation, and thus, qualitative detection and verification of the MUC1 glycosylation changes have potential diagnostic value. We have developed an ultrasensitive method to detect the changes in cholangiocarcinoma (CC), which produces MUC1, and applied it in the diagnostics development. The focused glycan analysis using 43-lectin-immobilized microarray could obtain the glycan profiles of sialylated MUC1 in 5 μL of sera. The high-throughput analysis detected disease-specific alterations of glycosylation, and the statistical analysis confirmed that use of Wisteria floribunda agglutinin (WFA) alone produced a diagnostic score sufficient for discriminating 33 CC cases from 40 hepatolithiasis patients and 48 normal controls (p < 0.0001). The CC-related glycosylation change was verified by the lectin-antibody sandwich ELISA with WFA in two cohorts: (1) 78 Opisthorchis viverrini infected patients without CC and 78 with CC, (2) 33 CC patients and 40 hepatolithiasis patients (the same cohort used for the above lectin microarray). The WFA positivity distinguished patients with CC (opisthorchiasis: p < 0.0001, odds ratio = 1.047; hepatolithiasis: p = 0.0002, odds ratio = 1.018). Sensitive detection of qualitative alterations of sialylated MUC1 glycosylation is indispensable for the development of our glycodiagnostic test for CC. © 2015 American Chemical Society.

Taokaew S.,Chulalongkorn University | Nunkaew N.,Chulalongkorn University | Siripong P.,National Cancer Institute of Thailand | Phisalaphong M.,Chulalongkorn University
Journal of Biomaterials Science, Polymer Edition | Year: 2014

Bacterial cellulose (BC) films containing an ethanolic extract of mangosteen peel were prepared and their physical, chemical, and anticancer properties were characterized. The cumulative absorption and release profiles of bioactive compounds in the films were determined based on total phenolic and α-mangostin content. The BC films were filled with total phenolic compounds expressed as gallic acid equivalent varying from 4.72 to 275.91 mg/cm3 dried film, and α-mangostin varying from 2.06 to 248.20 mg/cm3 dried film. A Fourier transform infrared spectroscopy evaluation showed that there were weak interactions between the functional groups of the extract and the BC. Decreases in the water absorption capacity and water vapor transmission rate of the modified films were detected. Release studies were performed using Franz diffusion cells. In a non-transdermal system, the release of bioactive compounds from the films depended on concentration, immersion time, and the pH of the dissolution medium. A transdermal diffusion study showed that 59-62% of total phenolic compounds that were initially loaded were released from the films and more than 95% of bioactive compounds released from the films were adsorbed into pig skin. Only very small amount of the bioactive compounds penetrated through pig skin and into phosphate and acetate buffers. In studies of anticancer abilities, the release of 2.0 g/ml α-mangostin from the BC films could suppress the growth of B16F10 melanoma (approximately 31% survival). With the release of α-mangostin at greater than 17.4-18.4 g/ml, less than 15 and 5% survival of B16F10 melanoma and MCF-7 breast cancer cells, respectively, was observed. © 2014 Taylor & Francis.

Pongtheerat T.,Rangsit University | Pakdeethai S.,Rangsit University | Purisa W.,National Cancer Institute of Thailand | Chariyalertsak S.,National Cancer Institute of Thailand | Petmitr S.,Mahidol University
Asian Pacific Journal of Cancer Prevention | Year: 2011

The GSTP1 gene encodes for a detoxification enzyme involved in protecting cells from carcinogens. In breast cancer, GSTP1 polymorphisms may produce lower effective enzyme detoxification properties and GSTP1 promoter hypermethylation may result in inactivation of GSTP1 expression. We therefore hypothesized an influence on progression of breast cancer. To study the effect of GSTP1 polymorphisms and CpG-island hypermethylation on GSTP1 promoter, PCR-RFLP and methylation-specific PCR techniques were used with 41 Thai breast-cancer patients. Associations between the codon 105 (A to G) genetic polymorphism, CpG-island hypermethylation, and clinico-pathological parameters were analyzed. GSTP1 hypermethylation was found in 26% of cases and the GSTP1 polymorphism in 14%. GSTP1 hypermethylation was significantly associated with breast cancer; lymph-node metastasis (P = 0.02) while GSTP1 polymorphism status significantly varied with progesterone receptor positivity (P = 0.04). No association was found between the GSTP1 polymorphism and methylation status. The results indicated that CpG-island hypermethylation of the GSTP1 promoter is associated with a biologically aggressive phenotype, but may not be related to the codon 105 (A to G) gene polymorphism in breast-cancer patients.

Discover hidden collaborations